WebJul 19, 2024 · About the OVAL Phase 3 Clinical Trial. OVAL (VB-111-701/GOG-3018) was an international, Phase 3, randomized, double-blind, placebo-controlled, clinical trial … WebApr 26, 2024 · In the phase 3 OVAL trial, women with recurrent, platinum-resistant ovarian cancer were randomized to receive paclitaxel in combination with either ofra-vec or placebo. In addition to the dual primary end points, secondary outcome measures include objective response rate and response by CA-125 levels.
VB-111 Hits Milestone in Phase III Platinum-Resistant …
WebMar 8, 2024 · OVAL (VB-111-701/GOG-3018) is an international Phase 3 randomized, pivotal registration-enabling clinical trial comparing a combination of ofra-vec (ofranergene obadevovec or VB-111) and paclitaxel to placebo plus paclitaxel, in adult patients with recurrent platinum-resistant ovarian cancer. WebJul 19, 2024 · The OVAL trial demonstrated that patients randomized to the combination of ofra-vec and paclitaxel had a median PFS of 5.29 months, versus 5.36 months for the … momma bear audits
Watch Tyler Perry
WebJul 20, 2024 · The phase 3 OVAL trial (NCT03398655) of ofranergene obadenovec (VB-111; VBL Therapeutics) in combination with paclitaxel has failed to meet its primary endpoint in improving progression-free survival (PFS) or overall survival (OS) in patients with platinum-resistant ovarian cancer. 1 WebSep 17, 2024 · OVAL (VB-111-701/GOG-3018) is an international Phase 3 randomized, pivotal registration-enabling clinical trial comparing a combination of VB-111 and paclitaxel to placebo plus paclitaxel, in... Web21 hours ago · The Blue Oval Company has some very interesting news related to BlueCruise hands-free or even AI-assisted driverless ... the E-SELF endeavor is a long-running two-and-a-half-year trial of V2I ... iams flaked wet cat food